TARACTAN
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Mar 1962
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 23h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TARACTAN is an injectable small-molecule antipsychotic approved in 1962 by Roche. The drug's specific mechanism of action and therapeutic indications are not publicly detailed in available sources. It represents a legacy neuroleptic from the first generation of antipsychotics.
LOE Approaching
With LOE approaching and minimal competitive pressure documentation (30% noted), this product is in late-stage decline with likely reduced commercial staffing.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TARACTAN offers limited career growth potential as the product approaches LOE with zero linked job opportunities. Roles are primarily defensive, focused on maintaining market access and formulary position in specialized psychiatric/institutional settings rather than driving expansion or innovation.
Brand Manager (maintenance/legacy)Field Sales Representative (institutional/psychiatric)
Worked on TARACTAN at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.